Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding

ABSTRACT The ANRS 12174 trial assessed the efficacy and tolerance of lopinavir (LPV)-ritonavir (LPV/r) prophylaxis versus those of lamivudine (3TC) prophylaxis administered to breastfed infants whose HIV-infected mothers were not on antiretroviral therapy. In this substudy, we assessed LPV/r and 3TC pharmacokinetics to evaluate the percentage of infants with therapeutic plasma concentrations and to discuss these data in the context of a prophylactic treatment. Infants from the South African trial site underwent blood sampling for pharmacokinetic study at weeks 6, 26, and 38 of life. We applied a Bayesian approach to derive the 3TC and LPV pharmacokinetic parameters on the basis of previously published pharmacokinetic models for HIV-infected children. We analyzed 114 LPV and 180 3TC plasma concentrations from 69 infants and 92 infants, respectively. A total of 30 LPV and 20 3TC observations were considered missing doses and discarded from the Bayesian analysis. The overall population analysis showed that 30 to 40% of the infants did not reach therapeutic targets, regardless of treatment group. The median LPV trough concentrations at weeks 6, 26, and 38 were 2.8 mg/liter (interquartile range [IQR], 1.7 to 4.4 mg/liter), 5.6 mg/liter (IQR, 3.2 to 7.7 mg/liter), and 3.4 mg/liter (IQR, 2.3 to 7.3 mg/liter), respectively. The median 3TC area under the curve from 0 to 12 h after the last drug intake were 5.6 mg · h/liter (IQR, 4.1 to 7.8 mg · h/liter), 5.9 mg · h/liter (IQR, 5.1 to 7.5 mg · h/liter), and 7.3 mg · h/liter (IQR, 4.9 to 8.5 mg · h/liter) at weeks 6, 26, and 38, respectively. Use of the therapeutic doses recommended by the WHO would have resulted in a higher proportion of infants achieving the targets. However, no HIV-1 infection was reported among these infants. These results suggest that the prophylactic targets for both 3TC and LPV may be lower than the therapeutic ones. For treatment, the WHO dosing guidelines should be suitable to maintain values above the therapeutic pharmacokinetic targets in most infants. (This study has been registered at ClinicalTrials.gov under identifier NCT00640263.)

[1]  T. C. Pereira,et al.  Effects of RNA Interference Therapy against Herpes Simplex Virus Type 1 Encephalitis , 2016, Antiviral therapy.

[2]  P. Musoke,et al.  Extended pre-exposure prophylaxis with lopinavir–ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial , 2016, The Lancet.

[3]  D. Moodley,et al.  Evaluation of adherence measures of antiretroviral prophylaxis in HIV exposed infants in the first 6 weeks of life , 2015, BMC Pediatrics.

[4]  K. Mayer,et al.  Pre-Exposure Prophylaxis to Prevent HIV Infection: Current Status, Future Opportunities and Challenges , 2015, Drugs.

[5]  S. Urien,et al.  Lopinavir/Ritonavir plus Lamivudine and Abacavir or Zidovudine dose Ratios for Paediatric Fixed-Dose Combinations , 2015, Antiviral therapy.

[6]  A. Anglemyer,et al.  Antiretroviral interventions for preventing breast milk transmission of HIV. , 2014, The Cochrane database of systematic reviews.

[7]  R. Tubiana,et al.  Determination of total and unbound concentrations of lopinavir in plasma using liquid chromatography-tandem mass spectrometry and ultrafiltration methods. , 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[8]  S. Urien,et al.  Concentration-response Model of Lopinavir/Ritonavir in HIV-1–infected Pediatric Patients , 2014, The Pediatric infectious disease journal.

[9]  A. Walker,et al.  The Pharmacokinetics and Acceptability of Lopinavir/Ritonavir Minitab Sprinkles, Tablets, and Syrups in African HIV-Infected Children , 2014, Journal of acquired immune deficiency syndromes.

[10]  L. Mansoor,et al.  Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection , 2014, International Journal of Clinical Pharmacy.

[11]  S. Urien,et al.  High Exposure to Zidovudine During the First 2 Weeks of Life and Concentration—Toxicity Relationships , 2013, Journal of acquired immune deficiency syndromes.

[12]  R. Haubrich,et al.  Pre-exposure prophylaxis for HIV infection: how antiretroviral pharmacology helps to monitor and improve adherence , 2013, Expert opinion on pharmacotherapy.

[13]  S. Urien,et al.  A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients , 2013, AIDS.

[14]  C. Kankasa,et al.  Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174 , 2012, BMC Infectious Diseases.

[15]  R. Yogev,et al.  Assessment of Lopinavir Pharmacokinetics With Respect to Developmental Changes in Infants and the Impact on Weight Band–Based Dosing , 2012, Clinical pharmacology and therapeutics.

[16]  M. Polak,et al.  Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. , 2011, JAMA.

[17]  Ronald N Hines,et al.  The ontogeny of drug metabolism enzymes and implications for adverse drug events. , 2008, Pharmacology & therapeutics.

[18]  J. Schapiro,et al.  Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. , 2006 .

[19]  D. Katzenstein,et al.  Safety and Trough Concentrations of Nevirapine Prophylaxis Given Daily, Twice Weekly, or Weekly in Breast-Feeding Infants From Birth to 6 Months , 2003, Journal of acquired immune deficiency syndromes.

[20]  J. Dieleman,et al.  Low Nevirapine Plasma Concentrations Predict Virological Failure in an Unselected HIV-1-Infected Population , 2003, Clinical pharmacokinetics.

[21]  S. Spector,et al.  Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. , 1998, The Journal of infectious diseases.